Hutchmed
HCMDrugs in Pipeline
12
Phase 3 Programs
5
Upcoming Catalysts
1
Next Catalyst
Jun 25, 2026
5dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
HCM Earnings Report
FQ end 2026-03
fruquintinib+sintilimab
Advanced Renal Cell Carcinoma
HMPL-306 Regimen
Acute Myeloid Leukemia
Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine
Metastatic Pancreatic Cancer
fruquintinib
Advanced Endometrial Cancer
HMPL-453
Advanced Intrahepatic Cholangiocarcinoma
HMPL-760 planned dose 1
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
HMPL-689
Relapsed/Refractory Lymphoma
HMPL-A251
Solid Tumors, Adult
Tazemetostat
Relapsed/Refractory Follicular Lymphoma With EZH2
Surufatinib
Neuroendocrine Tumors
Fruquintinib in Combination with Sintilimab
Advanced Solid Tumor
Surufatinib in combination with Gemcitabine
Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
fruquintinib+sintilimab | Phase 3 | Advanced Renal Cell Carcinoma | - | - |
HMPL-306 Regimen | Phase 3 | Acute Myeloid Leukemia | - | - |
Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine | Phase 3 | Metastatic Pancreatic Cancer | - | - |
fruquintinib | Phase 3 | Advanced Endometrial Cancer | - | - |
HMPL-453 | Phase 3 | Advanced Intrahepatic Cholangiocarcinoma | - | - |
HMPL-760 planned dose 1 | Phase 2 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | - | - |
HMPL-689 | Phase 2 | Relapsed/Refractory Lymphoma | - | - |
HMPL-A251 | Phase 2 | Solid Tumors, Adult | - | - |
Tazemetostat | Phase 2 | Relapsed/Refractory Follicular Lymphoma With EZH2 | - | - |
Surufatinib | Phase 2 | Neuroendocrine Tumors | - | - |
Fruquintinib in Combination with Sintilimab | Phase 2 | Advanced Solid Tumor | - | - |
Surufatinib in combination with Gemcitabine | Phase 2 | Solid Tumor | - | - |